To test this, OVA-specific CD8+ T cells from the spleen of OT-1 mice were co-cultured with BCR-ABL1+ B-ALL cells pretreated with either CD19@NP/17-DMAG plus imatinib or 17-DMAG plus imatinib, both in the presence of OVA peptide. This evidence concerns the gene CD8A and acute lymphoblastic leukemia.